Health Care • Biotechnology: Laboratory Analytical Instruments
$8.80 ▲ +0.38
(+4.51%)
MKT CAP: $40.1M • VOL: 50.0K
52W L $4 52W H $9
HBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $86.5M | $94.1M | $112.3M |
| YoY Revenue Growth % | -8.1% | -16.1% | — |
| Gross Profit | $49.9M | $54.8M | — |
| Gross Margin % | 57.7% | 58.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$48.6M | -$6.2M | $1.9M |
| Operating Margin % | -56.1% | -6.6% | 1.7% |
| Net Income (GAAP) | -$56.7M | -$12.4M | -$3.4M |
| EBITDA (Normalized) | -$47.6M | -$4.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $6.7M | $1.4M | $14.0M |
| Capital Expenditures (CapEx) | $1.3M | $2.6M | — |
| Free Cash Flow (FCF) | $5.5M | -$1.2M | $14.0M |
| FCF Margin % | 6.3% | -1.3% | 12.5% |
| Return on Invested Capital (ROIC %) | -45.0% | -8.3% | — |
| Cash & Short-Term Equivalents | $8.6M | $4.1M | — |
| Total Debt (Short + Long Term) | $35.9M | $0 | — |
| Total Stockholders' Equity | $13.7M | $63.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HBIO.